CD274 and neoplasm: The rationale behind the PC regimen lies in its potential to overcome these limitations: chemotherapy not only reduces tumor burden but may also induce immunogenic cell death, thereby enhancing tumor antigen presentation, while PD-1/PD-L1 inhibitors restore T cell activity and help to counteract immune evasion and resistance mechanisms.